| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
775,593 |
1,206,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,587,745 |
$9,420,070 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
60 |
105 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-11-27 |
4 |
AS |
$20.00 |
$40,000 |
D/D |
(2,000) |
47,420 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-11-27 |
4 |
OE |
$0.54 |
$1,080 |
D/D |
2,000 |
49,420 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-10-08 |
4 |
AS |
$19.88 |
$39,760 |
D/D |
(2,000) |
47,420 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-10-08 |
4 |
OE |
$0.54 |
$1,080 |
D/D |
2,000 |
49,420 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-22 |
4/A |
AS |
$22.00 |
$13,200 |
D/D |
(600) |
21,940 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-22 |
4 |
AS |
$22.00 |
$13,200 |
D/D |
(600) |
73,652 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-21 |
4/A |
AS |
$22.09 |
$17,674 |
D/D |
(800) |
22,540 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-21 |
4 |
AS |
$22.09 |
$17,674 |
I/I |
(800) |
74,252 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-15 |
4/A |
AS |
$22.01 |
$55,898 |
D/D |
(2,540) |
23,340 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-15 |
4 |
AS |
$22.01 |
$55,898 |
I/I |
(2,540) |
75,052 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-09-10 |
4 |
AS |
$20.59 |
$41,185 |
D/D |
(2,000) |
47,420 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-09-10 |
4 |
OE |
$0.54 |
$1,080 |
D/D |
2,000 |
49,420 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2015-09-08 |
4 |
AS |
$20.29 |
$198,544 |
I/I |
(9,785) |
70,385 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-03 |
4 |
AS |
$19.25 |
$24,082 |
D/D |
(1,251) |
25,880 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-09-01 |
4 |
AS |
$18.32 |
$23,560 |
I/I |
(1,286) |
0 |
|
- |
|
| Caldwell Jeremy S |
EVP, Chief Scientific Officer |
• – – |
2015-09-01 |
4 |
AS |
$18.32 |
$11,780 |
D/D |
(643) |
0 |
|
- |
|
| Grammer Elizabeth A |
VP, General Counsel |
• – – |
2015-09-01 |
4 |
AS |
$18.32 |
$16,360 |
D/D |
(893) |
0 |
|
- |
|
| Arasaratnam Narani |
VP, Corporate Controller |
• – – |
2015-08-31 |
4 |
A |
$13.99 |
$17,237 |
D/D |
1,232 |
1,232 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-08-31 |
4 |
A |
$13.99 |
$9,598 |
D/D |
686 |
1,282 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2015-08-18 |
4 |
AS |
$20.00 |
$22,080 |
I/I |
(1,104) |
80,170 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-08-06 |
4 |
AS |
$19.07 |
$38,140 |
D/D |
(2,000) |
46,666 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-08-06 |
4 |
OE |
$0.54 |
$1,080 |
D/D |
2,000 |
48,666 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2015-08-03 |
4 |
AS |
$20.00 |
$6,000 |
D/D |
(300) |
81,247 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-07-30 |
4/A |
AS |
$19.27 |
$38,755 |
D/D |
(2,011) |
25,880 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2015-07-30 |
4 |
AS |
$19.27 |
$38,755 |
I/I |
(2,011) |
75,581 |
|
- |
|
538 Records found
|
|
Page 18 of 22 |
|
|
0.17 (2.57%) 
